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This guideline is the result of an international consensus to provide a practical reference for 
setting dose prioritization and acceptance criteria for tumor volumes and organs at risk for 















The treatment of nasopharyngeal carcinoma (NPC) requires high radiation doses. The balance 
of the risks of local recurrence due to inadequate tumor coverage versus the potential damage 
to the adjacent organs at risk (OARs) is of critical mportance. With advancements in 
technology, high target conformality is possible. Nonetheless, to achieve the best possible 
dose distribution, optimal setting of dose targets and dose prioritization for tumor volumes 
and various OARs is fundamental. Radiation doses should always be guided by the ALARP 
(As Low As Reasonably Practicable) principle. There ar  marked variations in practice. This 
study aimed to develop a guideline to serve as a global practical reference. 
Methods 
A literature search on dose tolerances and normal tissue complications following treatment 
for NPC was conducted. In addition, published guidelines and protocols on dose prioritization 
and constraints were reviewed.  A text document and preliminary set of variants was 
circulated to a panel of international experts with publications and/or extensive experience in 
the field. An anonymized voting process was conducted to rank the proposed variants. A 
summary of the initial voting and different opinions expressed by members were then re-
circulated to the whole panel for review and re-consideration. Based on the comments of the 
panel, a refined second proposal was re-circulated to the same panel. The current guideline 
was based on majority voting following repeated iteration for final agreement.  
 
Results 
Variation in opinion among international experts was repeatedly iterated to develop a 
guideline describing appropriate dose prioritization and constraints. The percentage of final 
agreement on the recommended parameters and alternativ  views is shown. The rationale for 















Through this comprehensive review of available evidnce and interactive exchange of vast 
experience by international experts, a guideline was developed to provide a practical 
reference for setting dose prioritization and acceptance criteria for tumor volumes and OARs. 
The final decision on the treatment prescription should be based on the individual clinical 
















Radiation therapy (RT) for nasopharyngeal carcinoma (NPC) presents a unique challenge due 
to the anatomical proximity of target volumes to criti al organs at risk (OARs). Although 
NPC, especially the classical non-keratinizing type, is relatively radiosensitive, high doses are 
generally needed for eradication of gross tumor and the therapeutic margin for optimal tumor 
control is notoriously narrow. Even in the contemporary era of intensity-modulated 
radiotherapy (IMRT) with extensive use of concurrent chemotherapy, dosimetric inadequacy 
enforced by dose constraints on OARs remains one of the most important independent factors 
affecting treatment outcome. It is often difficult to achieve the optimal balance and trade-off 
between risks of local recurrence due to inadequate t mor coverage versus potential serious 
late complications; this results from the inevitably high doses to OARs in the case of 
advanced tumors with extensive locoregional infiltration [1]. Decisions on prioritization vary 
substantially depending on different philosophies. 
 
The advent of newer planning and treatment delivery t chnologies has led to an evolving 
capability to maximize dose conformity. Although there is little doubt that IMRT is superior 
in improving tumour control and reducing toxicities when compared with 2DRT, there is 
marked variation in the toxicities reported. In therial by Peng et al. [2], the incidence of 
temporal lobe necrosis was still as high as 13.1% and optic nerve/chiasm injury was 1.6% in 
the IMRT arm; in contrast, other studies have shown that it is possible to achieve similar local 
control with substantially lower rates of neurological toxicity, such as a temporal lobe 
necrosis rate of 0.2% [3].   
 
Standardizing the appropriate delineation of tumour targets for different dose levels, dose 
prioritization for tumour targets and the various OARs, and acceptance criteria for each 
parameter is fundamental for future study and progress. Unfortunately, accurate data on the 
tolerance doses of critical OARs remain scanty. There is also marked variation in the 
philosophy and practice amongst different institutions and clinicians with regards to the order 
of prioritisation and the exact maximum acceptable doses for the different OARs.  
 
Through a process of iterative development amongst i ternational experts, we aimed to 













contributors from major centres in Asia, Australia, North America, Middle East and Europe 
previously provided input into the publication of “xxxx” [4]. To address issues that could not 
be covered in the previous guideline, our goal for this document was to provide a practical 
reference to assist clinicians in deciding on the optimal RT planning process for NPC and the 





The following processes were used for evidence searching and development of the guideline: 
 
Firstly, an initial literature search on NPC-specific late complications was performed on 
December 2017 in PubMed using the following search terms: 
("intensity-modulated radiation therapy" OR "intensity-modulated radiotherapy" OR IMRT) 
nasopharyngeal ("late toxicity" OR "temporal lobe" OR brainstem OR visual OR optic OR 
eye OR hearing OR ear) 
Published treatment guidelines and dose constraints by various centers were also reviewed. 
This formed the initial set of planning dose prioritization and acceptance criteria for voting 
based on a modified Delphi process [5-18]. A preliminary set of proposed variants for 
planning dose prioritization and acceptance criteria was then drafted. In order to provide a 
pragmatic reference, both a “goal” OAR constraint and  variation acceptable for treatment in 
challenging situations (i.e. maximum acceptance crit ria (MAC)) were listed.  
 
Secondly, a panel of international experts was convened to develop the guideline. To ensure 
appropriate recommendations with international representation, criteria were set to include 
only members with publications on treatment outcome (tumour control and toxicity), and/or 
extensive experience specific to NPC in major academic centres from different parts of the 
world (including Asia, Middle East/Mediterranean Region, Oceania, Europe and North 
America). 
 
We used a modified Delphi process for developing the final guideline: the preliminary 
proposal, together with previously published guidelines and protocols (Table 1), was 
circulated among international experts for initial voting and comments. The initial percentage 













(Supplementary Table 1). The exact votes submitted w re anonymized, while summary of 
this initial voting and different opinions and proposed variants expressed by members were 
circulated to the whole panel for review and re-consideration. Based on the exchanged 
comments and supporting data, a refined second proposal was drafted after repeated iteration 
among the panel members, and circulated for another round of voting. The current, finalized 
guideline summarized in Table 2 was based on majority views.  
 
In order to identify additional evidence published since the initial manuscript was finalized, a 
new literature search using the same search terms was conducted in May 2019 to ensure 
comprehensiveness of this review including the latest published evidence. 256 articles were 
identified; using the PRISMA checklist approach, 211 were excluded after initial screening of 
the abstracts. Of the 35 potentially relevant articles reviewed, 11 were excluded as they were 
found to be irrelevant to the subject of this study. Among the 24 relevant articles, 18 were 
cited in this manuscript as they provided specific recommendations on OAR dose constraints 
based on the latest updated data from the institute.  
 
A figure illustrating the literature search summary is added in Supplementary Appendix I.  
 
No major inconsistencies or discrepancies with our recommendations were found except for 
one very recent article on the dose constraint for the brainstem [19]. This information was 
circulated to the panel and a brief description of the findings was added to the guideline text, 
but the unanimous feedback from panel members was that this could not be recommended as 
practice-changing without further validation. 
 
The strength of the recommendations was rated according to the Grading of 
Recommendations Assessment, Development and Evaluation (GRADE) system 
(Supplementary Table 2) [20]. The GRADE level of evid nce assigned for each OAR was 
initially discussed and drafted by the three senior authors; and circulated to all the authors as 
part of the manuscript review. There were no objections or changes to suggested GRADE 
assignments. The evidence on dose constraints was largely derived from retrospective 
studies. The percentages of agreement among the panel members in the final vote (together 
with the exact number of votes) were listed in the manuscript and Table 2. The alternative 
constraints suggested by dissenting experts were also shown to illustrate existing variations 
















Results and Discussion on the Recommendations 
 
Before proceeding to setting dose prioritization and constraints, appropriate contouring of 
various structures is the first fundamental requirement. An international guideline on 
contouring of clinical tumour target volumes has been published previously [4]. Many 
authors in this current guideline also participated in the development of guidelines on 
contouring of organs at risk specifically for NPC [21] and head and neck cancers [22] which 
serve as useful references. We recommend that a planning risk volume (PRV) be delineated 
around critical organs to account for set-up variability. While this set-up variability varies 
among different institutions, a margin of not less than 2mm was generally recommended 
based on the study by Van Herk [23]. 
 
Prioritisation of dose constraints  
A study by Yao et al [24] in a cohort of NPC patiens with gross tumour volume exceeding 60 
cm3, showed that the prescribed mean doses to brainstem PRV and optic chiasm PRV were 
68.13 Gy (± 4.74 Gy) and 66.54 Gy (± 8.62 Gy), respectively, which were far higher than the 
usual recommended dose constraints for these OARs. With IMRT treatment planning, setting 
the appropriate prioritization levels for different structures is fundamental for achieving the 
desired optimization of dose distribution. The general principle is to achieve full tumoricidal 
doses to the whole tumour target within the maximum tolerance dose of critical OARs. 
However, in the frequent situations in which a trade-off must be made, more than 90% of the 
expert panel agreed that the priority should be givn to the critical OAR(s) to avoid 
potentially lethal or highly morbid sequelae.  
 
When the treatment plan is unable to give adequate t mor target coverage and meet the dose 
constraints for priority 1 OARs, we suggest either adaptive re-planning or consideration of 
induction chemotherapy. A recent randomized study by Yang et al suggests that the strategy 
of restricting full therapeutic dose to the MRI-defin d volume that remains after induction 
chemotherapy, while ensuring that the pre-induction chemotherapy volume receives at least 
an intermediate dose (64 Gy) appears not to compromise 3-year local, regional and distant 













cohort of 212 NPC patients [25]. Whether these results will continue to hold should an even 
lower dose be used (to meet critical OAR constraints) remains to be seen. 
 
There was unanimous agreement that Priority 1 should inc ude the brainstem, spinal cord and 
optic chiasm, as damage to these serially arranged structures can result in catastrophic 
morbidity, and even mortality. Bilateral blindness due to damage to optic chiasm and/or both 
optic nerves is such a debilitating complication that t ere is universal agreement that at least 
the optic nerve on the less involved side should be included as Priority 1 for dose constraint. 
However, we would consider exceeding the commonly recommended MAC for the ipsilateral 
optic nerve (lowering to Priority 3) if this is unavoidable to achieve adequate doses to cover 
the tumour target, provided the patient consents to an increased risk of unilateral partial or 
complete loss of sight. The latter entails a careful xplanation of the relative importance of 
the different components and trade-offs during the decision process. 
 
There was also unanimous agreement that Priority 2 should include tumour Planning Target 
Volume (PTV). There was, however, variation as to whether the priority for Gross Tumour 
Volume (GTV) should be raised to Priority 1 because, although it may still not be feasible to 
achieve minimum D98% of the prescribed dose to 100% of the GTV, there would at least be 
greater attempts to achieve the highest feasible dos . Under such circumstances, the options 
for the most suitable compromise should be discussed with the patient. 
 
We recommend that the temporal lobes be included under Priority 2 as temporal lobe necrosis 
(TLN) can lead to serious disability and mortality. The study by Lam et al. [26] showed that 
54% of patients progressed to grade 4 severity at 5 years after the diagnosis of TLN 
(asymptomatic and symptomatic) and 5-year overall survival was only 35%. However, there 
was variation in the level of priority accorded forthis structure. 
 
There was also complete agreement that normal tissues in the oral cavity, post-cricoid 
pharynx, esophagus and glottic larynx should be assigned to Priority 4. There were variations 
as to whether the other structures should be set at Priority 3 or Priority 4. We recommend that 
the brachial plexus, pituitary gland, eyeball and lens be included as Priority 3; while cochlea, 
mandible and temporo-mandibular joints, thyroid, parotid and submandibular glands should 














Readers may wish to familiarize themselves with the DAHANCA Radiotherapy Guidelines 
2013 [14]. DAHANCA has a long history of producing RT guidelines, with dose-volume 
constraints and rules for prioritization. Instead of using two terms for constraints, “Desirable” 
and “Acceptable”, they distinguish between OAR dose and PRV dose. There are also some 
differences in the priority listing. In general, DAH NCA ranks PTV coverage lower than 
critical serial OARs, to allow compromises where thmargins are tight. 
 
The desired dose and acceptance criteria for different structures  
Brainstem 
The QUANTEC review [27] recommended that a small volume of brainstem (1-10 mL) may 
be irradiated to a maximum dose of 59 Gy using dose fractionation ≤2 Gy and a Dmax <64 Gy 
with a point dose <1 cc. Two studies have been report d from Sun Yat-Sen Cancer Center to 
assess brainstem injury incurred by doses higher than t at recommended by QUANTEC. The 
study (n=1544) by Li et al. [28] showed 59% of patien s received a Dmax ≥54 Gy, and 25% 
received ≥64 Gy, of whom two developed brainstem necrosis; both had received a Dmax dose 
≥76.4 Gy and a V55 ≥3.8 cc. Their most recent analysis by Huang et al. [19] on 6264 NPC 
patients showed that patients with Dmax ≥67.4 Gy (equivalent dose in 2-Gy fractions 
{EQD2}) had significantly higher incidence of brainstem injury (odds ratio = 25.29, 95% CI: 
8.63–74.14; P < 0.001) than those with lower dose. Dmax of 67.4 Gy (EQD2) was 
recommended as the dose constraint for brainstem, but the authors also concluded that further 
studies are needed to validate their findings. On the other hand, Yao et al. [29] reported an 
alarming incidence rate of 2.8% at 5 years in a cohort of 327 NPC patients. Among the 8 
patients with brainstem injury, seven (one fatal and o e hemiplegic) had Dmax and D0.1cc ≥ 
63.38 Gy and 60.89 Gy, respectively. 
 
Other studies showed that the volume of brainstem with high dose is also important: Uy et al. 
[30] reported a case of brainstem necrosis with a V54 of 4.7 cc.; Debus et al. [31] showed that 
a V50 >5.9 cc, V55 >2.7 cc, and V60 >0.9 cc were associated with brainstem toxicity. 
Schoenfeld et al. [32] further recommended to restrict the V55 to <0.1 cc.  
 
In view of the potential devastating consequence and risk of serious medico-legal 
implications by brainstem injury, while a higher dose (Dmax of 67.4 Gy) may be discussed as 
an option for patients with tumors encroaching the brainstem, a more conservative dose 













responded to this special vote) till more robust validation become available. 
 
Our final recommendation was to aim for a D0.03 cc PRV dose ≤54 Gy and MAC of 60 Gy. 
 
Level of agreement: 90% (18 of 20 voters) agreed on esirable dose (alternative suggestions 
ranged from 50-58 Gy); 90% (19 of 21 voters) agreed on MAC (alternative variants proposed 
ranged from 54-64 Gy). 




The QUANTEC review [33] suggests that at 2 Gy per fraction, the probability of myelopathy 
is 0.03% at 45 Gy and 0.2% at 50 Gy. 
Our final recommendation was to aim at a D0.03 cc PRV dose ≤45 Gy and MAC ≤50 Gy. 
 
Level of agreement: 100% (20 of 20 voters) agreed on esirable dose, 95% (20 of 21 voters) 
agreed on MAC (alternative variants proposed were up to 55 Gy).  
GRADE of recommendation: High 
 
 
Optic chiasm and optic nerve 
The QUANTEC review [34] suggested that the incidence of radiation-induced optic 
neuropathy (RION) was unusual for a Dmax <55 Gy, particularly for fraction sizes <2 Gy. The 
risk increases (3–7%) in the region of 55–60 Gy and becomes more substantial (>7–20%) for 
doses >60 Gy when fractionation schedules of 1.8–2.0 Gy are used. Similarly, in the study 
reported by Akagunduz et al. [35], a series of comprehensive visual tests showed that visual 
field and contrast sensitivity were affected significantly with V55 ≥ 50% and Dmean ≥ 50 Gy 
and visual evoked potential latency was affected significantly with Dmean ≥ 50 Gy, D5 ≥ 55 
Gy, and Dmax ≥ 60 Gy. For the chiasm, a significant detrimental effect of all parameters was 
observed on visual acuity as well.  
 
We set the same dose criteria for both structures as there were no data to suggest that their 
radiosensitivities were different. However, we suggest separate considerations for according 













dose ≤54 Gy and MAC of ≤60 Gy, for both structures.  
 
Level of agreement: 93% (14 of 15 voters) agreed on esirable dose for the optic chiasm and 
optic nerve, respectively (alternative variants proposed was 50 Gy). For the recommended 
MAC, the agreement level among the panel was 82% (14 of 7 voters) and 95% for optic 
chiasm (alternative variants proposed ranged from 54-56 Gy) and optic nerve (alternative 
variants proposed were up to 62 Gy), respectively. 




Gross tumour volume (GTV):  
The study by Ng et al. [1], showed that those who received at least 66.5 Gy to primary GTV 
were less likely to have local failure (odds ratio, 0.289; p = 0.020).  
 
Our final recommendation was to aim for a minimum dose of ≥68.6 Gy (98% dose) and to set 
a minimum acceptable criterion at 66.5 Gy (95% dose).  
 
Level of agreement: 78% (14 of 18 voters) agreed on esirable dose (alternative variants 
proposed ranged from 66-70 Gy); 80% (16 of 20 voters) agreed on acceptable dose. 
GRADE of recommendation: Moderate  
 
 
Planning target volume (PTV): 
Dose prescription at 3-4 levels at conventional fractionation was agreed upon by 73%, while 
18% would prescribe using 2 dose levels only. As discussed in the previous guideline on the 
contouring of CTVs [4], we recommend three levels of dose prescription in line with the 
general principles of ICRU: CTV1 for GTV with margin, CTV2 for high-risk 
structures/regions, and CTV3 for intermediate-low risk structures/regions for microscopic 
infiltration. Two commonly used prescription schemes are acceptable: either the 35-fraction 
(2 Gy per fraction) scheme with doses prescribed to 70, 63-60 and 56 Gy; or the 33-fraction 
(2.12 Gy per fraction) scheme with the doses prescribed to 69.96, 63-59.4, and 54 Gy. It 
should be pointed out that current NCCN Guidelines recommend restricting the prescribed 













neurological structures with larger fraction size. [36]  
 
Our final recommendation is to achieve ≥95% dose of the prescribed dose to 100% PTV or 
≥93% dose to ≥99% PTV.  
 
Regarding the issue of dose heterogeneity, we recommend restricting hot-spots ≥75 Gy to 
<10% PTV70 or ≥77 Gy to ≤5% PTV70 as the preferred criteria; and increased this to ≥75 
Gy to <20% PTV70 or ≥77 Gy to ≤10% PTV70 as the acceptable criteria. 
 
We acknowledge that there is an increasing tendency to accept higher dose heterogeneity and 
“hot spot” doses to ensure better dose conformality s suggested by the ICRU 83 report [37] 
or even deliberately giving a higher dose (80 Gy) to certain regions of GTV as a means of 
dose escalation/dose redistribution according to the tumor behavior as visualized on 
molecular imaging [38]; but 15% of panel members recommended to control the upper limit 
of the hot spot dose to not exceed 80 Gy. It is important to emphasize that while there is a 
move towards higher doses within the target volume these areas should be well away from 
the critical OAR – especially the brain stem to prevent any untoward neurological adverse 
events from the treatment itself. 
 
Level of agreement:  
• PTV dose prescription: 81% (17 of 21 voters) agreed to either the 35-fraction (2 Gy 
per fraction) scheme with the doses prescribed to 70, 63-60 and 56 Gy; or the 33-
fraction (2.12 Gy per fraction) scheme with the doses prescribed to 69.96, 63-59.4, 54 
Gy. 
• PTV min: 95% (19 of 20 voters) agreed on desirable dose (alternative variants 
proposed was aim for 100% of the PTV receiving full prescription dose), 90% (18 of 
20 voters) agreed on acceptable dose. 
• PTV hotspot: 86% (18 of 21 voters) agreed on desirable dose, 90% (18 of 20 voters) 
agreed on acceptable dose. 
GRADE of recommendation: High/Moderate for PTVmin; Moderate for PTV hotspot  
 
Temporal lobe:  













5% risk of symptomatic radiation necrosis is predicted to occur at an equivalent dose of 72 
Gy (range, 60–84); furthermore, they cautioned that the brain is especially sensitive to 
fraction sizes >2 Gy. Due to the close proximity of the temporal lobes to the nasopharynx, 
multiples studies have been reported in the NPC literature to evaluate the dose-volume effects 
on temporal lobe injury after IMRT. A study by Sun et al. [40] reported that a D0.5cc of 69 Gy 
may be the dose tolerance of the temporal lobe. However, subsequent studies suggested lower 
dose equivalents of 60.3 Gy (D2cc) [41], 62.8 Gy (D1cc) [6, 42] and 69 Gy (Dmax) [42] (at 2 
Gy/fraction) for a 5% probability of developing temporal lobe injury at 5 years. These 
findings concurred with a study reported by Su et al. [43], in which the probability of 
temporal lobe injury was ≤5% at 5 year if D1cc was less than 58 Gy; and Dmax was less than 
68 Gy. Furthermore, the volume of temporal lobe receiving low to moderate doses is also an 
important contributing factor for the development of emporal lobe injury.  
 
On the other hand, for patients with a locally advanced tumor, a reasonable balance between 
adequate tumor coverage and risk of temporal lobe injury is needed; and a dose limit of D1cc 
≤ 71.14 Gy [44] and Dmax ≤72 Gy [1] have been suggested for T4 disease. 
  
The final recommendation of the panel was to aim for a D0.03 cc PRV dose ≤ 65 Gy for T1-2 
tumors and ≤ 70Gy for T3-4 tumors; MAC ≤72 Gy should be confined to T3-4 tumors only. 
Based on the latest literature findings, we also acknowledge that D1cc may be a better 
parameter for future studies. 
 
Level of agreement: 85% (17 of 20 voters) agreed on esirable dose (alternative variants 
proposed ranged from 66-70 Gy irrespective of the tumour stage); 62% (13 of 21 voters) 
agreed on MAC dose for T3-4 tumors (alternative variants proposed were up to 74 Gy, but 
33% would not accept a MAC >70Gy). 
GRADE of recommendation: Moderate  
 
Brachial plexus: 
Damage to the brachial plexus may have a long latency period of 1 to 17 years (average 8.2 
years), but it can lead to significant morbidity of unilateral or bilateral arm or hand 
paraesthesia, weakness, as well as pain and muscular atrophy [45, 46]. A retrospective study 
by Cai et al. showed that patients with a therapeutic dose ≥66.8±2.8 Gy to lower cervical 













plexopathy [46]. Chen et al. showed that the incidence of brachial plexopathy increased 
dramatically when V70 exceeds 10% [47]. Thus, the brachial plexus should be outlined as an 
OAR as a study has shown that a large proportion of patients were exposed to doses 
exceeding the Radiation Therapy Oncology Group (RTOG) recommended dose constraints 
when the brachial plexus was not outlined [48]. Placing dose constraints on the brachial 
plexus can significantly decrease the irradiated volume and dose, without compromising 
adequate dose delivery to the target volume [49].  
 
In line with the recommendation by RTOG, our final recommendation is to aim at a D0.03 cc 
PRV dose ≤66 Gy, and MAC of ≤ 70 Gy. 
 
Level of agreement: 89% (16 of 18 voters) agreed on esirable dose (alternative variants 
proposed was ≤ 60 Gy); 85% (17 of 20 voters) agreed on acceptable dose (altern tive variants 
proposed was ≤ 66 Gy). 
GRADE of recommendation: Moderate  
 
 
Eyeball and lens: 
Jeganathan and colleagues have published an excellent r view of ocular risks from orbital 
and periorbital irradiation [50]. Similar to the considerations for the optic nerve, we would 
opt to accept exceeding these recommended MACs for ipsilateral structures if necessary, in 
order to attain adequate tumor dose coverage and the patient has consented to accepting 
increased risk. The contralateral, less involved side hould then be kept within the dose 
limits.  
 
Our final recommendation of the eyeball was to aim for a mean dose of ≤35 Gy and MAC of 
D0.03 cc ≤50 Gy. . For the lens, our final recommendation wasto aim for a D0.03 cc dose <6 Gy 
and MAC at D0.03 cc dose ≤15 Gy.  
 
Level of agreement:  
• Eyeball: 90% (18 of 20 voters) agreed on desirable dose (alternative variants proposed 
ranged from 25-45 Gy); 76% (16 of 21 voters) agreed on acceptable dose (alternative 













• Lens: 90% (18 of 20 voters) agreed on desirable dos, 82% (18 of 22 voters) agreed 
on acceptable dose. 
GRADE of recommendation: Moderate  
 
 
Pituitary (and hypothalamus) and thyroid glands: 
Even in the IMRT era, it has been reported that a significant number of patients, ranging from 
20-50%, develop some element of endocrine deficiency post-RT [51-56]. We recommend 
including the pituitary gland (and hypothalamus) under Priority 3, while setting the thyroid 
gland as Priority 4, because damage to the thyroid gland will lead to a deficiency of thyroid 
hormone alone and replacement is possible. In contrast, damage to the pituitary results in 
complex dysfunction of multiple hormones including sex hormones, cortisol and thyroid 
pathways, as well as growth hormones.  
 
For the pituitary, we recommend to aim for a D0.03cc dose ≤60 Gy and MAC of D0.03cc dose 
≤65 Gy. However, published data regarding the tolerance of the thyroid gland are scanty. We 
recommend to aim at V50 ≤60%, based on the study by Sachdev et al. (55); and MAC as V60 
≤10 cc. 
 
Level of agreement:  
• Pituitary: 79% (11 of 14 voters) agreed on desirable dose (alternative variants 
proposed ranged from 40-54Gy); 87% (13 of 15 voters) agreed on acceptable dose. 
• Thyroid: 88% (14 of 16 voters) agreed on desirable dose (alternative variants 
proposed were D0.03cc ≤45 Gy or Dmean ≤50 Gy); 89% (16 of 18 voters) agreed on 
acceptable dose (alternative variants proposed was D0.03cc dose ≤50 Gy). 




Due to the location and pattern of invasion of NPC, hearing impairment is one of the 
commonest toxicities in the IMRT era, especially for those who also receive cisplatin-based 
chemotherapy. QUANTEC [57] recommends that for conventionally fractionated RT, to 













be limited to ≤45 Gy (or more conservatively ≤35 Gy). Because a threshold for SNHL cannot 
be determined from the present data, to prevent SNHL the dose to the cochlea should be kept 
as low as possible. The study by Chan et al. [58] showed that the mean cochlea dose and 
concurrent cisplatin dose were important determinants of high-frequency SNHL, with an 
odds ratio of 1.07/Gy increase and 1.008/mg/m2 increase, respectively; it is thus 
recommended that the mean MAC to the cochlea should be owered to ≤47 Gy for patients 
treated with chemoradiotherapy. Similar findings have been reported by Wang et al. [59], 
with an accumulative cisplatin dose of ≥200 mg/m2 and radiation dose of 40 Gy to 0.1ml 
cochlea being predictive factors for the development of SNHL. 
 
Our final recommended dose was to aim for a mean dose of ≤45 Gy and MAC of mean dose 
≤55 Gy.  
 
Level of agreement: 90% (18 of 20 voters) agreed on esirable dose (alternative variants 
proposed ranged from 28-50 Gy), 86% (19 of 22 voters) agreed on acceptable dose 
(alternative variants proposed ranged from 32-52.5Gy). 




QUANTEC [60] recommends that severe xerostomia (long-term salivary function <25% of 
baseline) can usually be avoided if at least one parotid gland has been spared to a mean dose 
of less than 20 Gy or if both glands have been spared to a mean dose of less than 25 Gy. The 
study by Lee et al. [61] concurred that with this dose constraint, less than 33% of patients had 
xerostomia at 3 months and none had it at 12 months. However, this goal might be difficult to 
achieve, especially with larger tumours and those with gross nodal involvement. A study by 
Eisbruch et al. [62] reported that partial volume thresholds for prediction of reduced salivary 
flow were 67%, 45%, and 24% gland volumes receiving more than 15 Gy, 30 Gy, and 45 Gy, 
respectively, showing substantial preservation of salivary flow rates following RT with 
continued improvement over time.  
 
Our final recommendation is to aim for a mean dose of <26 Gy and MAC <30 Gy for ≥50% 














Level of agreement: 90% (18 of 20 voters) agreed on desirable dose (alternative variants 
proposed being mean dose <25Gy); 82% (18 of 22 voters) agreed on acceptable dose 
(alternative variants proposed ranged from mean dose ≤25-35 Gy). 
GRADE of recommendation: Moderate 
 
 
Mandible and temporomandibular joint (TMJ): 
The mandible and the TMJ are subject to late effects of radiation, leading to possible 
osteoradionecrosis (ORN) and joint stiffness of the TMJ. A literature review by Mendenhall 
et al. [63] found that the incidence of ORN is 5% to 10% with a median latency period of 1 to 
2 years or less. The likelihood of ORN depends on anumber of factors including primary site 
and extent of disease, dental status, treatment modality, RT dose, volume of mandible 
included in the planning target volume, RT fractionation schedule and technique, and dental 
extractions/root canal work.  
 
In the work of Ben-David et al., half of the patients received at least 70 Gy to ≥ 1% of the 
mandibular volume; no patients developed ≥ grade 2 ORN [64]. Similarly, Gomez et al. 
reported that no patients developed ORN using the dos  constraint of Dmax ≤70 Gy. [65] On 
the other hand, investigators from the MD Anderson Head and Neck Cancer Working Group 
reported that the volume effect might be more important than maximum dose. It was found 
that while the mandibular mean dose was significantly higher in the ORN cohort (48.1 vs 
43.6 Gy, p<0.0001), the maximum dose was, in fact, not statistically different. Thus, they 
recommended V44 <42% and V58 <25% to the mandible as reasonable DVH constraints for 
IMRT plan acceptability, when tumour coverage was not compromised [66].  
 
Our final recommendation was to aim for a D2% dose of ≤70 Gy, and MAC ≤75 Gy. 
 
Level of agreement: 95% (18 of 19 voters) agreed on esirable dose, 67% (14 of 21 voters) 
agreed on acceptable dose (alternative variants proposed ranged narrowly from 73-77 Gy). 

















unscheduled treatment breaks or failure to complete tr atment. Both radiotherapy and 
chemotherapy are independent factors for the risk of incurring acute mucosal toxicities. 
Sanguineti et al. [67] found that concurrent chemoradiotherapy increases the risk of mucosal 
Grade 3 toxicity approximately 4 times over RT alone, and it is equivalent to an extra of 6.2 
Gy to 21 cc of oral mucosa over a 7-week course. For patients receiving induction 
chemotherapy followed by chemo-radiation for head an  neck cancer, Bhide et al. [68] have 
derived similar dose response curves. Thus, lower doses to the oral cavity (if achievable) 
should be considered in patients undergoing concurrent chemo-radiotherapy. 
 
Our final recommendation is to aim for a mean dose of ≤40 Gy and MAC of ≤50 Gy.  
 
Level of agreement: 70% (14 of 20 voters) agreed on desirable dose (alternative variants 
proposed ranged from 35-45 Gy); 77% (17 of 22 voters) agreed on acceptable dose 
(alternative variants proposed ranged from 30-70 Gy).  
GRADE of recommendation: Moderate/Low 
 
 
Pharynx and constrictor muscles: 
Swallowing problems following RT increase with the addition of concomitant chemotherapy 
and with increased radiation dose to various structu es that are part of the swallowing 
mechanism [69]. While Feng et al. [70] found that all p tients who experienced aspiration as 
a late complication received mean pharyngeal constrictor doses of >60 Gy or more than 50% 
of the total pharyngeal constrictor volume received more than 65 Gy (V65 >50%), multiple 
series have reported a steeper dose effect relationship starting beyond 45 Gy to the 
pharyngeal wall. [71-73] Levendag et al. [74] showed that a mean dose of 50 Gy predicted a 
20% probability of late dysphagia; this probability increased sharply at mean dose > 55 Gy 
with the chance of dysphagia increasing by 19% withevery additional 10 Gy. QUANTEC 
[75] recommends that with the limited available data vailable, minimizing the volume of the 
pharyngeal constrictors and larynx receiving ≥60 Gy and reducing, when possible, the 
volume receiving ≥50 Gy is associated with reduced dysphagia/aspiration. 
 
We recommended a Dmean ≤45 Gy, and MAC ≤55 Gy. 
 













proposed ranged from 35-50 Gy); 64% (14 of 22 voters) agreed on acceptable dose 
(alternative variants proposed ranged widely from 45-70 Gy). 




The study by Vainshtein et al. [76] on voice and speech outcomes after IMRT to the neck 
region where the larynx is not a target, showed that amongst patients receiving mean glottic 
larynx (GL) doses of ≤20 Gy, >20-30 Gy, >30-40 Gy, >40-50 Gy, and >50 Gy; 10%, 32%, 
25%, 30%, and 63%, respectively, reported worse voice quality at 12 months compared with 
pre-treatment status (P=.011); similar results were also observed for speech impairment.  A 
study by Rancati et al. [77] on the incidence of subacute or late laryngeal oedema after RT for 
head and neck cancers showed a clear volume effect consistent with the parallel architecture 
of the larynx. The authors recommended an equivalent uniform dose of less than 30-35 Gy to 
reduce the risk of G2-G3 oedema. 
 
Initial proposals based on existing guidelines were to aim for mean dose of ≤45 Gy and MAC 
≤55 Gy to the glottic larynx in order to reduce adverse effects on speech and voice quality, as 
well as to avoid laryngeal oedema. However the agreement was only 45% (9/20). Among 
panellists accustomed to lower neck and supraclavicular onventionally planned fields 
matched to the IMRT fields (which effectively shield the larynx), their recommendation was 
to restrict the glottic dose to less than 35 Gy. Basing on the literature of other head and neck, 
a high proportion of panellists feel that attempts should always be made to minimize the 
laryngeal mean dose to less than 35 Gy, particularly as this was often achievable even for 
plans utilising a single whole-neck IMRT field. In a study on oropharyngeal cancers not 
extending to the larynx, a mean dose of 29 Gy was achievable [78].  
 
Level of agreement: the desirable dose finally recommended is 35 Gy and the agreement was 
75% (15 of 20 voters).  

















Murdoch-Kinch et al. [79] showed that with mean doses <39 Gy, submandibular gland 
salivary flow rates recovered over time at 2.2% per month. The unstimulated salivary flow 
rates decreased exponentially by 3% per Gy increase in m an dose, and this recovered 
substantially over time if mean dose was <39 Gy. Similarly, Murthy et al. [80] found that the 
dose tolerance of submandibular gland leading to a 50% complication risk at 1 year was 36 
Gy with a 2-2.5% reduction in the probability of severe xerostomia for every 1 Gy reduction 
in mean dose. QUANTEC [60] recommends that submandibular gland sparing to modest 
mean doses (<35 Gy) might reduce xerostomia symptoms.   
 
We recommended a mean dose of <35 Gy. No specific recommendation was set for MAC as 
there is no supporting data in the literature. 
 
Level of agreement: 81% (17 of 21 voters) agreed on esirable dose (alternative variants 
proposed included a higher dose of < 39 Gy). 





Chu et al. [81] carried out a population-based cohort study based on the claims data of the 
National Health Research Insurance Database of Taiwan and found that ischaemic stroke 
incidence rates were 2-fold higher in treated NPC patients than in reference populations, with 
a greater relative risk in younger patients. While th  exact dose tolerances for the carotid 
vessels have not been well established in the literature, a higher risk of carotid artery stenosis 
following RT for NPC has been reported [82-85]. Although specific recommendations cannot 
be made in view of the lack of supporting data; the dose to the carotid vessels should be 
recorded and kept to as low as reasonably achievabl. 
 



















This guideline was derived through extensive review of currently available evidence for 
setting dose prioritization and acceptance criteria to tumour volumes and OARs, 
supplemented by an iterative process of guideline development from an international expert 
panel to put forth best practice recommendations for this complex radiotherapy-treated 
disease. 
 
When initial variants were circulated among the expert anellists, initial levels of agreement 
were low for some parameters, such as doses for the larynx and the thyroid. There seemed to 
be a clear dichotomy between practitioners in the East and West, with Asian experts tending 
to accept higher doses. Although different interpretations of the evidence will always exist, 
through iterative voting and revisions to the initially controversial parameters, summary final 
recommendations were able to be issued by the panel.  
 
The guiding principle should always be ALARP (As Low As Reasonably Practicable), as per 
radiation safety principles. In cases in which there is difficulty in achieving adequate tumor 
coverage and doses while respecting the recommended dose constraints, consideration of the 
relative probability of tumor control balanced against the probabilistic likelihood of normal 
tissue damage should be undertaken. The current guideline provides a practical reference, 
although the final decision on the optimal balance of risk and best possible compromises 
should take into consideration the individual clinical situation and the patient’s own 
preferences. Multicentre collaborations to accumulate more accurate data on the radiation 
planning factors affecting the therapeutic ratio, identification of clinical and 
molecular/genetic factors for prediction of radiation sensitivity or resistance, and prospective 
















Supplementary Material (Appendix) 
Supplementary Table 1: Initial recommendations, % agreement and alternative suggestions.  
Supplementary Table 2: Quality of evidence and definitions 

















1. Ng WT, Lee MC, Chang AT, Chan OS, Chan LL, Cheung FY, et al. The impact of 
dosimetric inadequacy on treatment outcome of nasopharyngeal carcinoma with IMRT. Oral 
Oncol. 2014;50(5):506-12. 
 
2. Peng G, Wang T, Yang KY, Zhang S, Zhang T, Li Q et al. A prospective, randomized study 
comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional two-
dimensional radiotherapy for the treatment of nasopharyngeal carcinoma. Radiother Oncol. 
2012;104(3):286-93. 
 
3. Lee AW, Ng WT, Chan LL, Hung WM, Chan CC, Sze HC, et al. Evolution of treatment for 
nasopharyngeal cancer--success and setback in the itensity-modulated radiotherapy era. 




5. Chan JW, Parvathaneni U, Yom SS. Reducing radiation-related morbidity in the treatment 
of nasopharyngeal carcinoma. Future Oncol. 2017;13(5):425-31. 
 
6. Zeng L, Huang SM, Tian YM, Sun XM, Han F, Lu TX, et al. Normal Tissue Complication 
Probability Model for Radiation-induced Temporal Lobe Injury after Intensity-modulated 
Radiation Therapy for Nasopharyngeal Carcinoma. Radiology. 2015;276(1):243-9. 
 
7. Sun Y, Zhou GQ, Qi ZY, Zhang L, Huang SM, Liu LZ, et al. Radiation-induced temporal 
lobe injury after intensity modulated radiotherapy in nasopharyngeal carcinoma patients: a 
dose-volume-outcome analysis. BMC Cancer. 2013;13:397. 
 
8. Bhandare N, Mendenhall WM. A Literature Review of Late Complications of Radiation 
Therapy for Head and Neck Cancers: Incidence and Dose Response. J Nucl Med Radiat Ther 
2012 S2:009. 
 













Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the 
scientific issues. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S3-9. 
 
10. Ng WT, Lee MC, Hung WM et al. Clinical outcomes and patterns of failure after 
intensity-modulated radiotherapy for nasopharyngeal carcinoma. Int J Radiat Oncol Biol 
Phys 2011, 79(2):420-428. 
 
11. Ng WT, RK Ngan, SH Chan, et al. Management of nasopharyngeal carcinoma. In: J. 
Bernier (ed.). Head and Neck Cancer - Multimodality Management. 2nd ed. Switzerland: 
Springer; 2016. 
 
12. 2010 Nasopharyngeal Carcinoma Intensity Modulated Radiotherapy Target and Dose 
Design Guidelines. Expert consensus. Chin J Radiat Oncol, 2011,20(04): 267-269. (Article in 
Chinese) http://zhfszlxzz.yiigle.com/CN11303020112004/424433.htm 
 
13. Merlotti A, Alterio D, Vigna-Taglianti R et al: Technical guidelines for head and neck 
cancer IMRT on behalf of the Italian association of radiation oncology - head and neck 
working group. Radiat Oncol 2014, 9:264. 
 




15. Dose Objectives for Head and Neck IMRT Treatment Planning. Recommendation Report: 
A project developed by the Head and Neck Community of Practice of the Radiation 
Treatment Program of Cancer Care Ontario for circulation to Regional Cancer Programs.   
https://www.cancercareontario.ca/en/guidelines-advice/types-of-cancer/3186 
 
16. Lee N, Harris J, Garden AS et al. Intensity-modulated radiation therapy with or without 
chemotherapy for nasopharyngeal carcinoma: Radiation Therapy Oncology Group Phase II 
trial 0225. J Clin Oncol 2009, 27(22):3684-3690. 
 
17. Lee NY, Zhang Q, Pfister DG et al. Addition of bevacizumab to standard chemoradiation 













institutional trial. Lancet Oncol 2012, 13(2):172-180. 
 
18. NRG-HN001: Randomized Phase II and Phase III Studies of Individualized Treatment for 
Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic 
Acid (DNA). https://www.nrgoncology.org/Clinical-Trials/Protocol-Table 
 
19. Huang XD, Li YC, Chen FP, et al: Evolution and Dosimetric Analysis of MRI-detected 
Brainstem Injury Following Intensity Modulated Radiotherapy in Nasopharyngeal 
Carcinoma. Int J Radiat Oncol Biol Phys 2019. May 7. pii: S036 -3016(19)30694-7. doi: 
10.1016/j.ijrobp.2019.04.032. [Epub ahead of print] 
 
20. Guyatt GH, Oxman AD, Vist GE et al. GRADE: an emerging consensus on rating quality 






23. van Herk M. Errors and margins in radiotherapy. Semin Radiat Oncol. 2004 
Jan;14(1):52-64. 
 
24. Yao JJ, Chen FP, Zhou GQ, et al. A prospective study on radiation doses to organs at risk 
(OARs) during intensity-modulated radiotherapy for nasopharyngeal carcinoma patients. 
Oncotarget. 2016 Apr 19;7(16):21742-52. 
 
25. Yang H, Chen X, Lin S et al. Treatment outcomes after reduction of the target volume of 
intensity-modulated radiotherapy following induction chemotherapy in patients with 
locoregionally advanced nasopharyngeal carcinoma: A prospective, multi-center, randomized 
clinical trial. Radiother Oncol. 2018 Jan;126(1):37-42 
 
26. Lam TC, Wong FC, Leung TW, Ng SH, Tung SY. Clinical outcomes of 174 
nasopharyngeal carcinoma patients with radiation-induced temporal lobe necrosis. Int J 














27. Mayo C, Yorke E, Merchant TE. Radiation associated brainstem injury. Int J Radiat 
Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S36-41. 
 
28. Li YC, Chen FP, Zhou GQ, Zhu JH, Hu J, Kang DH et al. Incidence and dosimetric 
parameters for brainstem necrosis following intensity modulated radiation therapy in 
nasopharyngeal carcinoma. Oral Oncol. 2017 Oct;73:97-104 
 
29. Yao CY, Zhou GR, Wang LJ et al. A retrospective dosimetry study of intensity-modulated 
radiotherapy for nasopharyngeal carcinoma: radiation-induced brainstem injury and dose-
volume analysis. Radiat Oncol. 2018 Oct 3;13(1):194. 
 
30. Uy NW, Woo SY, The BS, et al. Intensity-modulated radiation therapy (IMRT) for 
meningioma. Int J Radiat Oncol Biol Phys. 2002 Aug 1;53(5):1265-70. 
 
31. Debus J, Hug EB, Liebsch NJ, O'Farrel D, Finkelstein D, Efird J et al. Brainstem 
tolerance to conformal radiotherapy of skull base tumors. Int J Radiat Oncol Biol Phys. 1997 
Dec 1;39(5):967-75. 
 
32. Schoenfeld GO, Amdur RJ, Morris CG, et al. Patterns of failure and toxicity after 
intensity-modulated radiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys. 
2008 Jun 1;71(2):377-8533. Kirkpatrick JP, van der Kogel AJ, Schultheiss TE. Radiation 
dose-volume effects in the spinal cord. Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 
Suppl):S42-9. 
 
34. Mayo C, Martel MK, Marks LB, Flickinger J, Nam J, Kirkpatrick J. Radiation dose-
volume effects of optic nerves and chiasm. Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 
Suppl):S28-35 
 
35. Ozkaya Akagunduz O, Guven Yilmaz S, Yalman D, et al. Evaluation of the Radiation 
Dose-Volume Effects of Optic Nerves and Chiasm by Ps chophysical, Electrophysiologic 
Tests, and Optical Coherence Tomography in Nasopharyngeal Carcinoma. Technol Cancer 



















38. Grégoire V, Thorwarth D, Lee JA. Molecular Imaging-Guided Radiotherapy for the 
Treatment of Head-and-Neck Squamous Cell Carcinoma: Does it Fulfill the Promises? Semin 
Radiat Oncol. 2018 Jan;28(1):35-45. 
 
39. Lawrence YR, Li XA, el Naqa I, Hahn CA, Marks LB, Merchant TE et al. Radiation 
dose-volume effects in the brain. I t J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S20-
7 
 
40. Sun Y, Zhou GQ, Qi ZY, Zhang L, Huang SM, Liu LZ, et al. Radiation-induced temporal 
lobe injury after intensity modulated radiotherapy in nasopharyngeal carcinoma patients: a 
dose-volume-outcome analysis. BMC Cancer. 2013;13:397. 
 
41. Feng M, Huang Y, Fan X, Xu P, Lang J, Wang D. Prognostic variables for temporal lobe 
injury after intensity modulated-radiotherapy of nasopharyngeal carcinoma. Cancer Med. 
2018 Mar;7(3):557-564 
 
42. Kong C, Zhu XZ, Lee TF et al. LASSO-based NTCP model for radiation-induced 
temporal lobe injury developing after intensity-modulated radiotherapy of nasopharyngeal 
carcinoma. Sci Rep. 2016 May 23;6:26378 
 
43. Su SF, Huang Y, Xiao WW et al. Clinical and dosimetric characteristics of temporal lobe 
injury following intensity modulated radiotherapy of nasopharyngeal carcinoma. Radiother 
Oncol. 2012 Sep;104(3):312-6. 
 
44. Huang J, Kong FF, Oei RW, Zhai RP, Hu CS, Ying HM. Dosimetric predictors of 
temporal lobe injury after intensity-modulated radiotherapy for T4 nasopharyngeal 
carcinoma: a competing risk study. Radiat Oncol. 2019 Feb 8;14(1):31. 
 
45. Gu B, Yang Z, Huang S, Xiao S, Zhang B, Yang L et al. Radiation-induced brachial 















46. Cai Z, Li Y, Hu Z, Fu R, Rong X, Wu R et al. Radi tion-induced brachial plexopathy in 
patients with nasopharyngeal carcinoma: a retrospective study. Oncotarget. 2016 Apr 5; 
7(14): 18887–18895. 
 
47. Chen AM, Wang PC, Daly ME, et al. Dose--volume odeling of brachial plexus-
associated neuropathy after radiation therapy for head-and-neck cancer: findings from a 
prospective screening protocol. Int J Radiat Oncol Biol Phys. 2014 Mar 15; 88(4):771-7. 
 
48. Feng G, Lu H, Liang Y, Chen H, Shu L, Lu S et al. Radiation dose to the brachial plexus 
in nasopharyngeal carcinoma treated with intensity-modulated radiation therapy: An 
increased risk of an excessive dose to the brachial plexus adjacent to gross nodal disease. Exp 
Ther Med. 2012 Aug;4(2):216-220. 
 
49. Jiang H, Lu H, Yuan H, Huang H, Wei Y, Zhang Y, Liu X et al. Dosimetric benefits of 
placing dose constraints on the brachial plexus in patients with nasopharyngeal carcinoma 
receiving intensity-modulated radiation therapy: a comparative study. J Radiat Res. 2015 
Jan;56(1):114-21. 
 
50. Jeganathan VS, Wirth A, MacManus MP. Ocular risks from orbital and periorbital 
radiation therapy: a critical review. Int J Radiat Oncol Biol Phys. 2011 Mar 1; 79(3):650-9. 
 
51. Huang S, Wang X, Hu C, Ying H. Hypothalamic-pituitary-thyroid dysfunction induced by 
intensity-modulated radiotherapy (IMRT) for adult patients with nasopharyngeal carcinoma. 
Med Oncol. 2013;30(4):710. 
 
52. Sommat K, Ong WS, Hussain A, Soong YL, Tan T, Wee J, et al. Thyroid V40 Predicts 
Primary Hypothyroidism After Intensity Modulated Radi tion Therapy for Nasopharyngeal 
Carcinoma. Int J Radiat Oncol Biol Phys. 2017;98(3):574-80. 
 
53. Lee V, Chan SY, Choi CW, Kwong D, Lam KO, Tong CC, et al. Dosimetric Predictors of 
Hypothyroidism After Radical Intensity-modulated Radiation Therapy for Non-metastatic 














54. Zhai RP, Kong FF, Du CR, Hu CS, Ying HM. Radiation-induced hypothyroidism after 
IMRT for nasopharyngeal carcinoma: Clinical and dosimetric predictors in a prospective 
cohort study. Oral Oncol. 2017;68:44-9. 
 
55. Luo R, Li M, Yang Z, Zhan Y, Huang B, Lu J, et al. Nomogram for radiation-induced 
hypothyroidism prediction in nasopharyngeal carcinoma after treatment. Br J Radiol. 
2017;90(1070):20160686. 
 
56. Sachedv S, Refaat T, Bacchus ID, Sathiasselan V, Mittal BB. Thyroid V50 Highly 
Predictive of Hypothyroidism in Head-and-Neck Cancer Patients Treated With Intensity-
modulated Radiotherapy (IMRT). Am J Clin Oncol. 2017 Aug;40(4):413 417. 
 
57. Bhandare N, Jackson A, Eisbruch A, Pan CC, Flickinger JC, Antonelli P et al. Radiation 
therapy and hearing loss. Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S50-7. 
 
58. Chan SH, Ng WT, Kam KL, Lee MC, Choi CW, Yau TKet al. Sensorineural hearing loss 
after treatment of nasopharyngeal carcinoma: a longitudinal analysis. Int J Radiat Oncol Biol 
Phys. 2009 Apr 1;73(5):1335-42. 
 
59. Wang J, Chen YY, Tai A et al. Sensorineural Hearing Loss after Combined Intensity 
Modulated Radiation Therapy and Cisplatin-Based Chemotherapy for Nasopharyngeal 
Carcinoma. Transl Oncol. 2015 Dec;8(6):456-62 
 
60. Deasy JO, Moiseenko V, Marks L, Chao KS, Nam J, Eisbruch A. Radiotherapy dose-
volume effects on salivary gland function. I t J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 
Suppl):S58-63. 
 
61. Lee TF, Fang FM. Quantitative analysis of normal tissue effects in the clinic 
(QUANTEC) guideline validation using quality of life questionnaire datasets for parotid 
gland constraints to avoid causing xerostomia during head-and-neck radiotherapy. Radiother 
Oncol. 2013;106(3):352-8. 
 













relationships in parotid salivary glands following conformal and intensity-modulated 
irradiation of head and neck cancer. Int J Radiat Oncol Biol Phys. 1999;45(3):577-87. 
 
63. Mendenhall WM, Suarez C, Genden EM, de Bree R, Strojan P, Langendijk JA, et al. 
Parameters Associated With Mandibular Osteoradionecr sis. Am J Clin Oncol. 2018 
Dec;41(12):1276-1280. 
 
64. Ben-David MA, Diamante M, Radawski M, et al. Lack of osteoradionecrosis of the 
mandible after intensity-modulated radiotherapy for head and neck cancer: likely 
contributions of both dental care and improved dose di tributions. Int J Radiat Oncol Biol 
Phys. 2007 Jun 1; 68(2):396-402. Epub 2007 Feb 22. 
 
65. Gomez DR, Estilo CL, Wolden SL, et al. Correlation of osteoradionecrosis and dental 
events with dosimetric parameters in intensity- modulated radiation therapy for head-and-
neck cancer. Int J Radiat Oncol Biol Phys 2011; 81:e207-e213.  
 
66. MD Anderson Head and Neck Cancer Working Group. Dose-volume correlates of 
mandibular osteoradionecrosis in Oropharynx cancer patients receiving intensity-modulated 
radiotherapy: Results from a case-matched comparison. Radiother Oncol. 2017;124(2):232- 
 
67. Sanguineti G, Sormani MP, Marur S, Gunn GB, RaoN, Cianchetti M, et al. Effect of 
radiotherapy and chemotherapy on the risk of mucositis during intensity-modulated radiation 
therapy for oropharyngeal cancer. Int J Radiat Oncol Biol Phys. 2012;83(1):235-42. 
 
68. Bhide SA, Gulliford S, Schick U, Miah A, Zaidi S, Newbold K, et al. Dose-response 
analysis of acute oral mucositis and pharyngeal dysphagia in patients receiving induction 
chemotherapy followed by concomitant chemo-IMRT for head and neck cancer. Radiother 
Oncol. 2012 Apr;103(1):88-91. 
 
69. Paleri V, Roe JW, Strojan P, Corry J, Grégoire V, Hamoir M et al. Strategies to reduce 
long-term postchemoradiation dysphagia in patients with head and neck cancer: an evidence-
based review. Head Neck. 2014 Mar;36(3):431-43. 
 













cancer aiming to reduce dysphagia: early dose-effect relationships for the swallowing 
structures. Int J Radiat Oncol Biol Phys 2007; 68:1289–1298. 
 
71. Doornaert P, Slotman BJ, Rietveld DHF, et al. The mean radiation dose in pharyngeal 
structures is a strong predictor of acute and persist nt swallowing dysfunction and quality of 
life in head and neck radiotherapy. Int J Radiat Oncol Biol Phys 2007; 69(Suppl):55.  
 
72. Caglar HB, Allen AM, Othus M, et al. Dose to the larynx predicts for swallowing 
complications following IMRT and chemotherapy. Int J Radiat Oncol Biol Phys 
2008;72:1110–1118.  
 
73. O’Meara EA, Machtay M, Moughan J, et al. Association between radiation doses to 
pharyngeal regions and severe late toxicity in head and neck cancer patients treated with 
concurrent chemoradiotherapy—An RTOG analysis. Int J Radiat Oncol Biol Phys 
2007;69(Suppl):54.  
 
74. Levendag PC, Teguh DN, Voet P. et al. Dysphagia disorders in patients with cancer of the 
oropharynx are significantly affected by the radiation therapy dose to the superior and middle 
constrictor muscle: a dose-effect relationship. Radiother Oncol 2007;85:64–73. 
 
75. Rancati T, Schwarz M, Allen AM, Feng F, Popovtzer A, Mittal B et al. Radiation dose-
volume effects in the larynx and pharynx. Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 
Suppl):S64-9. 
 
76. Vainshtein JM, Griffith KA, Feng FY, Vineberg KA, Chepeha DB, Eisbruch A. Patient-
reported voice and speech outcomes after whole-neck i tensity modulated radiation therapy 
and chemotherapy for oropharyngeal cancer: prospective longitudinal study. Int J Radiat 
Oncol Biol Phys. 2014;89(5):973-80. 
 
77. Rancati T, Fiorino C, Sanguineti G. NTCP modeling of subacute/late laryngeal edema 
scored by fiberoptic examination. Int J Radiat Oncol Biol Phys. 2009;75(3):915-23. 
 
78. Webster GJ, Rowbottom CG, Ho KF, Slevin NJ, Mackay RI. Evaluation of larynx-sparing 















79. Murdoch-Kinch CA, Kim HM, Vineberg KA, Ship JA, Eisbruch A. Dose-effect 
relationships for the submandibular salivary glands and implications for their sparing by 
intensity modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2008;72(2):373-82. 
 
80. Murthy V, Lewis S, Kannan S, Khadanga CR, Rangarajan V, Joshi K et al. Submandibular 
function recovery after IMRT in head and neck cancer: A prospective dose modelling study. 
Radiother Oncol. 2018 Oct;129(1):38-43. 
 
81. Chu CN, Chen PC, Bai LY, Muo CH, Sung FC, Chen SW. Young nasopharyngeal cancer 
patients with radiotherapy and chemotherapy are most pr ne to ischaemic risk of stroke: a 
national database, controlled cohort study. Clin Otolaryngol. 2013;38(1):39-47. 
 
82. Steele SR, Martin MJ, Mullenix PS, Crawford JV,Cuadrado DS, Andersen CA. Focused 
high-risk population screening for carotid arterial stenosis after radiation therapy for head and 
neck cancer. Am J Surg. 2004;5:594–598.  
 
83. Lam WW, Leung SF, So NM, Wong KS, Liu KH, Ku PK, Yuen HY, Metreweli C. 
Incidence of carotid stenosis in nasopharyngeal carcinoma patients after radiotherapy. 
Cancer. 2001;92:2357–2363.  
 
84. Cheng SW, Ting AC, Lam LK, Wei WI. Carotid stenosis after radiotherapy for 
nasopharyngeal carcinoma. Arch Otolaryngol Head Neck Surg. 2000;126:517–521.  
 
85. Huang TL, Hsu HC, Chen HC, Lin HC, Chien CY, Fang FM, Huang CC, Chang HW, 
Chang WN, Huang CR, et al. Long-term effects on carotid intima-media thickness after 
















NPC-specific protocol H&N protocol 
  







NRG HN001 (18) 
China 
(12) 
AIRO (13) DAHANCA (14) 
Ontario 
(15) 
  Goal Acceptable     Goal Acceptable   Goal Acceptable OAR PRV   
Brainstem  





≤54 Gy or 
≤1% vol. >60 
Gy 
≤54 Gy or ≤1% 
PRV >60 Gy 





≤54 Gy ≤60 Gy ≤54 Gy ≤60 Gy 









45 Gy or ≤1cc 
vol. >50 Gy 
 ≤45 Gy or ≤1% 
PRV >50 Gy 






or  PRV 
≤44-48 Gy 
46 Gy or  
PRV ≤48-
50 Gy 
≤45 Gy ≤50 Gy 









54 Gy or ≤1% 
vol. >60 Gy 
≤50 Gy or PRV 
≤54 Gy 







≤54 Gy ≤60 Gy ≤50 Gy 
GTV-T & GTV-N 







Not stated Not stated Not stated 
Not 
stated 
Not stated Not stated Not stated 
CTV min Not stated Not stated Not stated 
CTV6996 





Not stated  CTV1 Not Stated 
  
 
    >65.1 Gy 65.1–60 Gy     95%-107% dose   
   
    
CTV6270 
- 99 % 
vol. 















    
>58.6 
Gy; 
58.6–55 Gy     95% doses   
  
 
    
CTV5940 
- 99 % 
vol. 
          
  
 
    >55.2 Gy 55.2–52 Gy         
  
 
    
CTV5412 
- 99 % 
vol 
          
        >50.2 Gy 50.2–45 Gy         
CTV Hotspot                 


































dose PTV63, 59.4,54 PTV 6270, 5940, 5412 
      ≥95% dose 
 or ≥99 % 
PTV ≥95% 
dose 



















          
    ≥93% dose   
≥99% 
PTV 
                
        
≥93% 
dose 























        
<20% 







≤ 20%  
PTV ≥ 
80 Gy 





        
≤1 cc outside   
tissue  ≥77 Gy 
Mean dose ≤74 
Gy 

















≤54 Gy ≤60-66 Gy 
  54 Gy* or  
≤1% vol. >60 
Gy 




0.03 cc ≤56 
Gy 








1cc Max Max     0.03 cc Max Max Max   
<65 Gy <72-75 Gy 
60 Gy or  
≤1% vol. >65 
Gy 
Not stated  <70 Gy ≤72 Gy 
≤60 Gy 
or  ≤1% 
vol. >65 
Gy 
≤60 Gy  ≤65 Gy  ≤60 Gy Not stated 
Mandible & TM 
joint 
≤1cc ≤1cc ≤1cc 0.03 cc ≤1cc  Max mandible   Max 0.1cc 
>70 Gy  >75 Gy 
>75 Gy or  
Max 70 Gy 
>75 Gy or Max 
70 Gy 






joint > 70 
Gy  






≤1 cc   Max 0.03 cc Max Max     Max 
>66 Gy Not stated ≤66 Gy <66 Gy ≤70 Gy ≤66 Gy ≤60 Gy  ≤66 Gy  Not stated ≤63 Gy 
Parotid glands (at 




≥50% of 1 
gland 
Mean of 1 
gland 
Mean of 1 
gland 
Mean of 1 gland Mean 
Mean of 1 
gland 
≥60% of 1 
gland Mean  
Mean of 1 
gland 
<26 Gy <30 Gy 
<26 Gy;  
³50% of 1 
gland <30 Gy; 
or ≥20cc of 
both glands 
<20 Gy 
<26 Gy; or  
³50% of 1 gland 
<30 Gy; or 
≥20cc of both 
glands <20 Gy 







<26 Gy; or  
³50% of 1 
gland <30 




Gy   
. <30 Gy 
both glands: ≤26 
Gy; contralateral 
gland: ≤20 Gy 
<26 Gy; or  








(stem cell region) 














Max         Mean Max Mean   
≤60 Gy ≤65 Gy Not stated Not stated Not stated ≤50 Gy ≤50 Gy ≤30 Gy Not stated  
Lens 
Max   Max 0.03 cc Max Max     Max 
≤6 Gy ≤10 Gy Not stated < 25 Gy <15 Gy ≤25 Gy <4 Gy <6 Gy Not stated ≤5 Gy 
Eyeball 
Max Mean Mean Max 0.03 cc Max Retina - Max Max Max 















Mean Mean ≤5% vol. 0.03 cc Mean Mean Mean Max 
<50 Gy ≤55 Gy <50 Gy ≥55 Gy ≤55 Gy ≤45 Gy <50 Gy  <52.5 Gy  
≤45 Gy or  ≤5% 
vol. ≥55 Gy 
≤45 Gy 
Glottic larynx 
Mean Mean Mean Mean Mean Max   Mean Mean 
<45 Gy <45 Gy <45 Gy <40 Gy ≤45 Gy 
supraglottis 






  ≤44 Gy 







Mean   Mean Mean Mean Max Mean Mean 









≤ 30 Gy 
Esophagus: 



















<40 Gy <50 Gy 
Tongue: <55 
Gy or ≤ 1% 
vol. >65 Gy 
<40 Gy <40 Gy 
Mean 
≤40 Gy 
Not stated  Not stated ≤30 Gy  ≤40 Gy 
Submandibular 
gland 
        Mean Mean   Mean   
Not stated Not stated Not stated Not stated <35 Gy <35 Gy Not stated <35 Gy Not stated 
Lips 
              Mean   
Not stated Not stated Not stated Not stated 
Not 
stated 
Not stated  ≤20 Gy Not stated 
Thyroid           
  















    
Organ at Risk (OAR) 
Acceptance Criteria   
  Desirable Dose Acceptable Dose   
Organ Priority 
% Agree Disagree 
Specification Dose 
% agree 




 (of those who 
voted) 
  








      
Brainstem 1 
17/17 
  D0.03 cc ≤54 Gy 
18/20 
≤60 Gy# 
19/21   
100% 90% 90% High/Moderate 
        
Spinal cord 1 
17/17 
  D0.03 cc ≤45 Gy 
20/20 
≤50 Gy  
20/21   
100% 100% 95% High 
        
Optic chiasm 1 
16/17 
(3) – 1/17 D0.03 cc ≤54 Gy 
14/15 
≤60 Gy  
14/17   
94% 93% 82% High/Moderate 
        
GTV-T & GTV-N 2 
10/16 
(1) – 6/16 Min ≥68.6 Gy (98% dose) 
14/18 
66.5 Gy (95% dose) 
16/20   
63% 78% 80% Moderate 




15/17 (1) – 1/17 
Prescription 
dose  
PTV70, 63, 60, 56 = 35#                                                                
PTV 69.96, 63, 60, 54 = 33# 
17/21 
      
88% (4) – 1/17 81%   
        
PTV min 2 
13/15 (1) – 1/15 
Min 
≥95% PTV 100% or 19/20 
95% PTV ≥ 95% dose 
18/20   
87% (4) – 1/15 ≥99% PTV ≥93% dose 95% 90% High / Moderate 
            
PTV hotspot 2 
14/15 
(4) – 1/15 Max 
<5% PTV70 ≥ 75 Gy  or     18/21 
<10% PTV70 ≥75 Gy or       
≤20% PTV70 ≥77 Gy 
18/20   
93% ≤10% PTV70 ≥77 Gy 86% 90% Moderate 
          
Temporal lobe  2 
11/17 (1) – 1/17 
D0.03 cc 
≤65 Gy for early stage and 
≤70 Gy for late stage 
17/20 
≤72 Gy 
13/21   
65% (3) – 4/17 85% 62% Moderate 
  (5) – 1/17       
          
Optic nerve 
3 12/17 (1) – 2/17 
D0.03 cc ≤54 Gy 
19/20 
≤60 Gy 
21/22   
Bilateral: 
1 
71% (2) – 2/17 95% 95% High / Moderate 
    (3) – 1/17       
            
Parotid gland 4 
12/17 (2) – 2/17 
Mean        <26 Gy 
18/20 
<30 Gy (at least one 
gland)  
18/22   
71% (3) – 2/17 90% 82% Moderate 













Mandible & TM 
joint 
4 
14/17 (3) – 2/17 
D2% ≤70 Gy 
18/19 
≤75 Gy 
14/21   
82% (5) – 1/17 95% 67% Moderate 
          
Brachial plexus 3 
13/15 (2) – 1/15 
D0.03 cc <66 Gy 
16/18 
≤70 Gy 
17/20   
87% (5) – 1/15 89% 85% Moderate 
          
Pituitary  
4 
11/14 (2) – 1/14 
D0.03 cc ≤60 Gy 
11/14 
≤65 Gy 
13/15   
(and 
hypothalamus) 
79% (3) – 1/14 79% 87% Moderate / Low 
    (5) – 1/14       
            
Lens 3 
12/17 (1) – 1/17 
D0.03 cc ≤6 Gy 
18/20 
≤15 Gy 
18/22   
71% (4) – 2/17 90% 82% Moderate 
  (5) – 2/17       
          
Eyeball  3 
14/17 (2) – 2/17 
Mean <35 Gy 
18/20 
≤50 Gy  ( D0.03 cc ) 
16/21   
82% (4) – 1/17 90% 76% Moderate 
          
Cochlea 4 
13/17 (2) – 2/17 
Mean  ≤45 Gy 
18/20 
≤55 Gy 
19/22   
76% (3) – 2/17 90% 86% Moderate 
          
Glottic larynx 4 
16/17 
(3) – 1/17 Mean 
≤35 Gy 15/20 
≤50 Gy  ( D2% ) 
10/22   
94%   75% 45%   
   
 
 
  Moderate 






13/17 (3) – 2/17 




Moderate / Low 
76% (5) – 2/17 85% 64%   
Oral cavity 
(excluding PTV) 4 
13/17 (3) – 2/17 
Mean  <40 Gy 
14/20 
<50 Gy 
17/22   
76% (5) – 2/17 70% 77% Moderate / Low 
  







(5) – 1/14 Mean  <35 Gy 
17/21 
    
  
93% 81% Moderate 
      
Thyroid 4 
12/14 (3) – 1/14 
  V50<70% 
14/16 
VS60> 10cc 
16/18   
86% (5) – 1/14 88% 89% 
















Table 2. OAR prioritization and Acceptance Criteria - final agreement results. 
 
#A recent study by Huang et al [19] suggested Dmax of 67.4 Gy (equivalent dose in 2-Gy fractions) as the dose constraint for brainstem. While this may be discussed as an option for patients with tumors encroaching the 
brainstem, a conservative dose acceptance criterion (to aim for a D0.03 cc PRV dose ≤54 Gy and MAC of 60 Gy) was preferred among our panel (25/25 [100%] of those who responded to this special vote) for this general 
guideline till more robust validation become available. 
 
 
 
